Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing compound doai
Reexamination Certificate
2007-02-28
2009-11-24
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing compound doai
C564S280000
Reexamination Certificate
active
07622508
ABSTRACT:
The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I):wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 6313312 (2001-11-01), Banks et al.
patent: 6469030 (2002-10-01), Farrar et al.
patent: 6479516 (2002-11-01), Gibson et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6610711 (2003-08-01), Armer et al.
patent: 6992090 (2006-01-01), Le Bourdonnec et al.
patent: 7049335 (2006-05-01), McHardy et al.
patent: 7056930 (2006-06-01), Coe et al.
patent: 7087749 (2006-08-01), Dolle et al.
patent: 7241887 (2007-07-01), Coe et al.
patent: 2002/0025948 (2002-02-01), Banks et al.
patent: 2003/0181447 (2003-09-01), Boyd et al.
patent: 2004/0186135 (2004-09-01), Dolle et al.
patent: 2004/0204453 (2004-10-01), McHardy et al.
patent: 2004/0254190 (2004-12-01), Liras
patent: 2005/0085508 (2005-04-01), Fukutomi et al.
patent: 2007/0105863 (2007-05-01), Dolle et al.
patent: 2008/0207676 (2008-08-01), Dalziel et al.
patent: WO 2004/089908 (2004-10-01), None
patent: WO 2004/089909 (2004-10-01), None
Lu et al., “Substituted Bridged Phenyl Piperidines: Orally Active Growth Hormone Secretagogues”, Bioorganic & Medicinal Chemistry Letters 13, pp. 1817-1820 (2003).
U.S. Appl. No. 12/218,383, Colson et al.
U.S. Appl. No. 12/229,636, Saito et al.
U.S. Appl. No. 12/229,664, Saito et al.
U.S. Appl. No. 12/229,737, Long et al.
U.S. Appl. No. 12/229,748, Long et al.
Le Bourdonnec et al., “trans-3,4-Dimethyl-4-(3-carboxamidophenyl)piperidines: A Novel Class of μ-Selective Opioid Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 13 pp. 4459-4462 (2003).
Le Bourdonnec et al., “Elucidation of the Bioactive Conformation of theN-Substitutedtrans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Class of μ-Opioid Receptor Antagonists”, Journal of Medicinal Chemistry, vol. 49, pp. 7278-7289 (2006).
Le Bourdonnec et al., “Synthesis and Pharmacological Evaluation of Novel Octahydro-1H-pyrido[1,2-a]pyrazine as μ-Opioid Receptor Antagonists”, Journal of Medicinal Chemistry, vol. 49, pp. 7290-7306 (2006).
Diaz et al., “SAR and Biological Evaluation of Noveltrans-3,4-dimethyl-4-arylpiperidine Derivatives as Opioid Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 15 pp. 3844-3848 (2005).
Church Timothy J.
Dalziel Sean
Jacobsen John R.
Jiang Lan
Long Daniel D.
Hagenah Jeffrey A.
Rahmani Niloofar
Saxon Roberta P.
Seaman D. Margaret
Theravance Inc.
LandOfFree
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111597